CompletedPhase 2NCT02074059

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

Studying Neonatal acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Windtree Therapeutics
Principal Investigator
Robert Segal, MD, FACP
Windtree Therapeutics, Inc.
Intervention
Lucinactant for Inhalation(drug)
Enrollment
80 target
Eligibility
All sexes
Timeline
20142015

Study locations (11)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02074059 on ClinicalTrials.gov

Other trials for Neonatal acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Neonatal acute respiratory distress syndrome

← Back to all trials